echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Diabetologia: The expression of IGFBP-1 in human type 2 diabetic glomeruli decreases and regulates β1-integrin/FAK signaling in human podocytes

    Diabetologia: The expression of IGFBP-1 in human type 2 diabetic glomeruli decreases and regulates β1-integrin/FAK signaling in human podocytes

    • Last Update: 2021-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Purpose: Podocyte loss or damage is one of the earliest features observed in the pathogenesis of diabetic nephropathy (DKD), which is the main cause of end-stage renal failure in the world


    Podocyte loss or damage is one of the earliest features observed in the pathogenesis of diabetic nephropathy (DKD), which is the main cause of end-stage renal failure worldwide


    Results: Data from the PIMA DKD cohort and Nephroseq database showed that in the early stages of human type 2 DKD, glomerular IGFBP-1 was significantly reduced


    Table glomerular IGFBP-1 decreases in the early stage of type 2 DKD

    Table glomerular IGFBP-1 decreases in the early stage of type 2 DKD

    Figure 1 Changes in glomerular IGFBP expression observed in type 2 DKD


    Figure 1 Changes in glomerular IGFBP expression observed in type 2 DKD


    Figure 2 The expression of IGFBP-1 in human glomeruli and podocytes is regulated by FoxO1


    Figure 2 The expression of IGFBP-1 in human glomeruli and podocytes is regulated by FoxO1


    This study confirmed the new role of IGFBP-1 in the regulation of podocyte function, and in the early stage of type 2 DKD, by reducing the activity of FoxO1, the glomerular expression of IGFBP-1 was reduced


    Lay AC, Hale LJ, Stowell-Connolly H,et al, IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytes.


    IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytes.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.